You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 14, 2025

Claims for Patent: 11,331,292

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,331,292

Title:	Methods of treatment of cholestatic diseases
Abstract:	The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Inventor(s):	Remy HANF
Assignee:	Genfit SA
Application Number:	US16/894,110
Patent Claims:	1. A method for the treatment of primary biliary cholangitis, the method comprising orally administering elafibranor at a dose between 70 mg and 130 mg per administration to a subject with primary biliary cholangitis. 2. The method according to claim 1, wherein the subject is a patient with primary biliary cholangitis and inadequate response to ursodeoxycholic acid. 3. The method according to claim 1, the method comprising orally administering once daily 80 or 120 mg/day of elafibranor. 4. The method according to claim 1, the method comprising orally administering once daily 80 mg/day of elafibranor. 5. The method according to claim 1, the method further comprising administering to the subject another anti-cholestatic agent. 6. A method for the treatment of primary biliary cholangitis, comprising orally administering elafibranor at a dose between 70 mg and 130 mg per administration in combination with ursodeoxycholic acid to a subject with primary biliary cholangitis and inadequate response to ursodeoxycholic acid. 7. The method according to claim 6, wherein elafibranor is administered at a dose of 80 mg per administration. 8. The method according to claim 6, wherein elafibranor is orally administered once daily at a dose of 80 mg/day. 9. The method according to claim 6, wherein elafibranor is administered at a dose of 120 mg per administration. 10. The method according to claim 6, wherein elafibranor is orally administered once daily at a dose of 120 mg/day. 11. A method for the treatment of primary biliary cholangitis, comprising orally administering 80 mg/day of elafibranor once daily in combination with ursodeoxycholic acid to a subject with primary biliary cholangitis and inadequate response to ursodeoxycholic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.